(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Russian drone slams into block of flats in deadly wave of strikes across Kyiv - 2Figure out How to Adjust Work, Life, and an Internet based Degree
- 3‘Ukrainian housewives’ and Skyranger delays – German defense poster child Rheinmetall is in hot water
- 4Gaza humanitarian efforts reach key milestone as UNICEF vaccinates some 13,000 children
- 5Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- 7 Methods for further developing Rest Quality
- This Huge Ocean Beast Shifts Sharks’ Evolutionary Timeline
- Brazil judge orders government to add JBS subsidiary to 'dirty list' for slavery
- Becoming amazing at Arranging Pay Raises
- Four new luxury hotel openings in Italy you need to know about
- Fears of global aluminum shortages intensify
- 7 Countries Where Newcomers Feel Most Welcome, and 3 Where They Often Don’t
- Governments take targeted action as fuel prices hit retail
- New trailer for 'Bridgerton' Season 4 teases Benedict's love story: Watch it here
